Dosage guide
Coenzyme Q10 dosage
Coenzyme Q10 dosing: typical range, frequency, half-life, onset, routes. Evidence-tiered.
At a glance
- Typical dose
- 200mg
- Half-life
- 34hr
- Frequency
- 1 to 3 times daily with a fat-containing meal
- Routes
- oral
Protocol
- 1
Measure the dose
Typical Coenzyme Q10 dose is 200 mg (100 to 200 mg/day for general use; 200 to 300 mg/day for heart failure adjunct; 300 mg/day in divided doses for migraine prevention). Use a weight-based calculator for individual adjustments.
Open tool → - 2
Set the frequency
Administer 1 to 3 times daily with a fat-containing meal. Half-life of 34 hours anchors the dosing interval.
Open tool → - 3
- 4
Monitor for side effects
Watch for: mild GI upset (rare); headache (rare); insomnia at very high doses. Stop or reduce dose if tolerability breaks down.
Why this dose
Mobile electron carrier between Complex I/II and Complex III of the mitochondrial electron transport chain. Ubiquinol form acts as a lipid-soluble antioxidant in cell membranes and regenerates oxidized vitamin E.
The typical dose (200 mg) reflects 100 to 200 mg/day for general use; 200 to 300 mg/day for heart failure adjunct; 300 mg/day in divided doses for migraine prevention. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.
How to administer
Coenzyme Q10 is administered via the oral route. Oral dosing is straightforward: take with water, with or without food unless specifically noted.
Onset of action runs around 6 hours after administration. Peak effect lands near 4 weeks post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.
Half-life note: Plasma half-life ~33 to 35 hours; oral bioavailability 2 to 3% for ubiquinone, 5 to 8% for ubiquinol soft-gels
Cycling and tolerance
No cycling; continuous daily use is standard
Effects to expect at typical dose
- Q-SYMBIO trial showed 43% reduction in major cardiovascular events at 300 mg/day in heart failure
- Reduces statin-induced myalgia in some patients at 100-200 mg/day per Banach 2014 meta-analysis
- Migraine prophylaxis at 300 mg/day daily; AHS lists at Level B for prevention
- Ubiquinol absorbs 2-3x better than ubiquinone in adults over 60
- Plasma CoQ10 falls 15-40% with chronic statin therapy
- Small blood pressure reduction (3-5 mmHg systolic) at 100-200 mg/day
Best-graded outcomes
- A Plasma CoQ10 in statin users : Restores statin-induced depletion (Statin-treated adults with CoQ10 supplementation).
- B Major cardiovascular events in heart failure : 43 to 54% relative risk reduction (NYHA III-IV heart failure (Q-SYMBIO, KISEL-10)).
- B Statin-induced myalgia : Moderate reductions per Banach 2014 (Statin-treated adults with myalgia).
Side effects and interactions
Common side effects
- mild GI upset (rare)
- headache (rare)
- insomnia at very high doses
Notable interactions
- warfarin (moderate): structural similarity to vitamin K may modestly reduce warfarin efficacy; monitor INR
- chemotherapy (oxidative-stress-dependent agents) (moderate): theoretical interference; coordinate with oncology team
- antihypertensives (minor): additive blood pressure-lowering at high doses
- statins (minor): statins reduce CoQ10 synthesis; CoQ10 supplementation does not affect statin efficacy
Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Coenzyme Q10 profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.
Regulatory snapshot
- WADA status
- allowed
- DEA / Rx
- Not scheduled
- Pregnancy
- Limited safety data; precautionary use at standard doses
- Legal status
- Dietary supplement (most jurisdictions); prescription cardiac medication in Japan
Do not use if
- active warfarin therapy without monitoring (modest interaction with INR)
Related calculators
Related research